secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvalent, Inc. (NUVL)
CIK:        0001861560
Form:       8-K
Filed at:   2022-03-29T23:59:59+00:00
Accession:  0001193125-22-087372
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvalent reports $17.3M Q4 loss; IND cleared for ALK inhibitor NVL-655
----------------------------------------------------------------------

- Q4 2021 net loss $17.3M; full-year net loss $46.3M, vs $14.6M in 2020.
- Cash, equivalents, marketable securities $288.1M as of Dec 31, 2021; runway into 2024.
- FDA cleared IND for NVL-655 (ALK-selective); ALKOVE-1 Phase 1/2 to start Q2 2022.
- ARROS-1 trial of NVL-520 (ROS1) actively enrolling Phase 1 patients.
- Discovery pipeline targeting ALK resistance and HER2 exon 20; 2 candidate nominations expected in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861560/000119312522087372/0001193125-22-087372-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861560/000119312522087372/d307870d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-087372

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer